{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:36:28Z","timestamp":1707525388478},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,18]]},"DOI":"10.7759\/cureus.49005","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T14:14:40Z","timestamp":1700316880000},"source":"Crossref","is-referenced-by-count":0,"title":["Significant Weight Gain With the Administration of Lurasidone and Valproic Acid in Schizophrenia and Bipolar Disorder Patients"],"prefix":"10.7759","author":[{"given":"Shohei","family":"Okura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuji","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Schizophrenia and obesity: impact of antipsychotic medications","volume":"65","author":"Wirshing DA","year":"2004","unstructured":"Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry. 2004, 65:13-26.","journal-title":"J Clin Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903286388","article-title":"Lurasidone: a new drug in development for schizophrenia","volume":"18","author":"Meyer JM","year":"2009","unstructured":"Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009, 18:1715-26. 10.1517\/13543780903286388","journal-title":"Expert Opin Investig Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16m10698","article-title":"Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study","volume":"77","author":"Loebel AD","year":"2016","unstructured":"Loebel AD, Silva R, Goldman R, Watabe K, Cucchiaro J, Citrome L, Kane JM. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry. 2016, 77:1672-80. 10.4088\/JCP.16m10698","journal-title":"J Clin Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":"Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications","volume":"12","author":"Verrotti A","year":"2011","unstructured":"Verrotti A, D'Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev. 2011, 12:e32-43. 10.1111\/j.1467-789X.2010.00800.x","journal-title":"Obes Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1515\/dmdi-2014-0005","article-title":"Lurasidone drug-drug interaction studies: a comprehensive review","volume":"29","author":"Chiu YY","year":"2014","unstructured":"Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact. 2014, 29:191-202. 10.1515\/dmdi-2014-0005","journal-title":"Drug Metabol Drug Interact"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.06.013","article-title":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","volume":"27","author":"Calabrese JR","year":"2017","unstructured":"Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol. 2017, 27:865-76. 10.1016\/j.euroneuro.2017.06.013","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214530","article-title":"A behavioral weight-loss intervention in persons with serious mental illness","volume":"368","author":"Daumit GL","year":"2013","unstructured":"Daumit GL, Dickerson FB, Wang NY, et al.. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013, 368:1594-602. 10.1056\/NEJMoa1214530","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013006.pub2","article-title":"Interventions for the management of obesity in people with bipolar disorder","volume":"7","author":"Tully A","year":"2020","unstructured":"Tully A, Smyth S, Conway Y, Geddes J, Devane D, Kelly JP, Jordan F. Interventions for the management of obesity in people with bipolar disorder. Cochrane Database Syst Rev. 2020, 7:CD013006. 10.1002\/14651858.CD013006.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61817-6","article-title":"Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey","volume":"373","author":"Thornicroft G","year":"2009","unstructured":"Thornicroft G, Brohan E, Rose D, Sartorius N, Leese M, INDIGO Study Group. Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet. 2009, 373:408-15. 10.1016\/S0140-6736(08)61817-6","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/162596-significant-weight-gain-with-the-administration-of-lurasidone-and-valproic-acid-in-schizophrenia-and-bipolar-disorder-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:04Z","timestamp":1707509164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/162596-significant-weight-gain-with-the-administration-of-lurasidone-and-valproic-acid-in-schizophrenia-and-bipolar-disorder-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.49005","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,18]]}}}